

CYP51A1 Antibody (Center)

Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP8874C

Product Information

Application IHC-P, FC, WB, E

Primary Accession Q16850 Q4R8S6 **Other Accession** Reactivity Human **Predicted** Monkey Host Rabbit Clonality Polyclonal Isotype Rabbit IgG **Clone Names** RB17075 57278 **Calculated MW** 250-279 **Antigen Region**

Additional Information

Gene ID 1595

Other Names Lanosterol 14-alpha demethylase, LDM, CYPLI, Cytochrome P450 51A1,

Cytochrome P450-14DM, Cytochrome P45014DM, Cytochrome P450LI, Sterol

14-alpha demethylase, CYP51A1, CYP51

Target/Specificity This CYP51A1 antibody is generated from rabbits immunized with a KLH

conjugated synthetic peptide between 250-279 amino acids from the Central

region of human CYP51A1.

Dilution IHC-P~~1:100~500 FC~~1:10~50 WB~~1:1000 E~~Use at an assay dependent

concentration.

Format Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide.

This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation

followed by dialysis against PBS.

Storage Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store

at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions CYP51A1 Antibody (Center) is for research use only and not for use in

diagnostic or therapeutic procedures.

Protein Information

Name CYP51A1 (<u>HGNC:2649</u>)

Synonyms CYP51

Function Sterol 14alpha-demethylase that plays a critical role in the cholesterol

biosynthesis pathway, being cholesterol the major sterol component in mammalian membranes as well as a precursor for bile acid and steroid hormone synthesis (PubMed:20149798, PubMed:8619637, PubMed:9559662). Cytochrome P450 monooxygenase that catalyzes the three-step oxidative removal of the 14alpha-methyl group (C-32) of sterols such as lanosterol (lanosta-8,24-dien-3beta-ol) and 24,25- dihydrolanosterol (DHL) in the form of

formate, and converts the sterols to

4,4-dimethyl-5alpha-cholesta-8,14,24-trien-3beta-ol and 4,4-

dimethyl-8,14-cholestadien-3beta-ol, respectively, which are intermediates of

cholesterol biosynthesis (PubMed:20149798, PubMed:8619637,

PubMed: 9559662). Can also demethylate substrates not intrinsic to mammals, such as eburicol (24-methylene-24,25- dihydrolanosterol), but at a lower rate

than DHL (PubMed: 9559662).

Cellular Location Endoplasmic reticulum membrane {ECO:0000250 | UniProtKB:Q64654};

Single-pass membrane protein. Microsome membrane

{ECO:0000250|UniProtKB:Q64654}; Single-pass membrane protein

Tissue Location Ubiquitously expressed with highest levels in testis, ovary, adrenal, prostate,

liver, kidney and lung


Background

CYP51A1 is a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This endoplasmic reticulum protein participates in the synthesis of cholesterol by catalyzing the removal of the 14alpha-methyl group from lanosterol.

References


Matsuura, K., et.al., J. Biol. Chem. 280 (10), 9088-9096 (2005) Wang, Y., et.al., J. Biol. Chem. 283 (39), 26332-26339 (2008)


Images




Western blot analysis of lysate from LNCap cell line, using CYP51A1 Antibody (Center)(Cat. #AP8874c). AP8874c was diluted at 1:1000 at each lane. A goat anti-rabbit IgG H&L(HRP) at 1:5000 dilution was used as the secondary antibody. Lysate at 35ug.

Formalin-fixed and paraffin-embedded human prostate carcinoma reacted with PAX3 Antibody (N-term), which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical







CYP51A1 Antibody (Center) (Cat. #AP8874c) flow cytometry analysis of HL-60 cells (bottom histogram) compared to a negative control cell (top histogram).FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.